​

Palvella Therapeutics (PVLA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

PVLA Stock Forecast

Palvella Therapeutics (PVLA) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $228.50, with a high of $246.00 and a low of $207.00. This represents a 79.44% increase from the last price of $127.34.

PVLA Stock Rating

Palvella Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 1 Strong Buy (9.09%), 10 Buy (90.91%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 10 1 Strong Sell Sell Hold Buy Strong Buy

PVLA Price Target Upside V Benchmarks

TypeNameUpside
StockPalvella Therapeutics79.44%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3627
Avg Price Target$237.33$236.83$203.59
Last Closing Price$127.34$127.34$127.34
Upside/Downside86.38%85.98%59.88%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26-15---15
Sep, 26-15---15
Aug, 26-15---15
Jul, 26-15---15
Jun, 26-16---16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2026Ryan DeschnerRaymond James$226.00$122.1685.00%77.48%
Oct 12, 2026H.C. Wainwright$246.00$138.7777.27%93.18%
Sep 21, 2026Chardan Capital$240.00$150.5659.40%88.47%
Aug 05, 2026Truist Financial$207.00$154.1034.33%62.56%
Aug 05, 2026Canaccord Genuity$232.00$151.9952.64%82.19%
Jul 22, 2026Andrew FeinH.C. Wainwright$270.00$143.9487.58%112.03%
May 12, 2026Stephens$220.00$122.0980.19%72.77%
Feb 24, 2026Truist Financial$210.00$120.4174.40%64.91%
Feb 24, 2026Chardan Capital$210.00$118.6177.05%64.91%
Feb 24, 2026Stifel Nicolaus$250.00$119.26109.63%96.32%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 16, 2026Raymond JamesStrong BuyStrong Buyhold
Oct 16, 2026William BlairOutperforminitialise
Jul 22, 2026H.C. WainwrightBuyBuyhold
May 12, 2026StephensOverweightinitialise
Mar 24, 2026H.C. WainwrightBuyBuyhold
Feb 24, 2026H.C. WainwrightBuyBuyhold
Feb 02, 2026Cowen & Co.BuyBuyhold
Dec 16, 2025Cowen & Co.BuyBuyhold
Dec 16, 2025Raymond JamesStrong BuyStrong Buyhold
Dec 15, 2025BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-7.83$-3.71--
Avg Forecast$-3.70$-2.77$-5.41$-2.81
High Forecast$-3.02$-1.60$-1.48$-1.37
Low Forecast$-4.37$-3.93$-12.67$-4.16
Surprise %111.62%33.94%--

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported----
Avg Forecast$50.00K--$5.62M
High Forecast$50.00K--$5.62M
Low Forecast$50.00K--$5.62M
Surprise %----

Net Income Forecast

$-45M $-36M $-27M $-18M $-9M $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-17.43M$-41.72M--
Avg Forecast$-8.22M$-6.15M$-15.75M$-6.15M
High Forecast$-6.72M$-3.56M$-3.29M$-3.05M
Low Forecast$-9.73M$-8.75M$-28.20M$-9.26M
Surprise %111.97%577.77%--

PVLA Forecast FAQ

Is Palvella Therapeutics stock a buy?

Palvella Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Palvella Therapeutics is a favorable investment for most analysts.

What is Palvella Therapeutics's price target?

Palvella Therapeutics's price target, set by 11 Wall Street analysts, averages $228.5 over the next 12 months. The price target range spans from $207 at the low end to $246 at the high end, suggesting a potential 79.44% change from the previous closing price of $127.34.

How does Palvella Therapeutics stock forecast compare to its benchmarks?

Palvella Therapeutics's stock forecast shows a 79.44% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Palvella Therapeutics over the past three months?

  • October 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Palvella Therapeutics’s EPS forecast?

Palvella Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-5.41, marking a 45.82% increase from the reported $-3.71 in 2025. Estimates for the following years are.

What is Palvella Therapeutics’s revenue forecast?

Palvella Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for.

What is Palvella Therapeutics’s net income forecast?

Palvella Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-15.748M, representing a -62.25% decrease from the reported $-41.715M in 2025. Projections indicate .